Xenon Pharmaceuticals XENE Short- and long-term operating lease liabilities
Short- and long-term operating lease liabilities at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.
The official record: Xenon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xenon Pharmaceuticals's short- and long-term operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xenon Pharmaceuticals's short- and long-term operating lease liabilities?
- Xenon Pharmaceuticals (XENE) reported short- and long-term operating lease liabilities of -$349K in Q1 2026.
- How has Xenon Pharmaceuticals's short- and long-term operating lease liabilities changed year-over-year?
- Xenon Pharmaceuticals's short- and long-term operating lease liabilities decreased by 13.7% year-over-year, from -$307K to -$349K.
- What is the long-term trend for Xenon Pharmaceuticals's short- and long-term operating lease liabilities?
- Over 3 years (2022 to 2025), Xenon Pharmaceuticals's short- and long-term operating lease liabilities has grown at a 29.3% compound annual growth rate (CAGR), from -$600K to -$1.3M.